Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06478576

Study on Multibranched Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysm

Led by Lifetech Scientific (Shenzhen) Co., Ltd. · Updated on 2024-07-12

73

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this study is to evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)

CONDITIONS

Official Title

Study on Multibranched Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysm

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 80 years
  • Diagnosed with thoracoabdominal aortic aneurysm meeting criteria such as maximum diameter over 50 mm, rapid growth, or related symptoms
  • Anatomical suitability for stent graft including specific landing zone diameters and lengths
  • Feasible iliofemoral artery and upper extremity access
  • Ability to understand the trial, voluntarily participate, sign informed consent, and complete follow-up
Not Eligible

You will not qualify if you...

  • Ruptured aortic aneurysm with unstable condition
  • Aneurysmal aortic dissection
  • Infected or mycotic aortic aneurysm
  • Systemic or local infection increasing graft infection risk
  • Occlusion of major arteries such as superior mesenteric, celiac trunk, or renal artery
  • Need for simultaneous coverage or embolisation of both internal iliac arteries
  • Severe stenosis, calcification, or thrombus at stent-graft landing zone
  • Acute coronary syndrome within 6 months
  • Transient ischemic attack or ischemic stroke within 3 months
  • Significant liver or kidney function abnormalities
  • Severe pulmonary insufficiency preventing general anesthesia
  • Severe coagulation dysfunction
  • Major surgery or intervention within 30 days prior
  • Allergy to contrast agents, anticoagulants, antiplatelets, stent graft materials, or delivery system components
  • Connective tissue diseases such as lupus, Marfan syndrome, Ehlers-Danlos syndrome, or Behcet's disease
  • Takayasu arteritis
  • Serious vital organ dysfunction or other severe diseases
  • Pregnancy, planning pregnancy, or breastfeeding
  • Participation in other clinical trials within last 3 months
  • Life expectancy less than 1 year
  • Not suitable for endovascular repair based on investigator judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chinese PLA General Hospital

Beijing, China

Actively Recruiting

Loading map...

Research Team

W

Wei Xu, PM

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here